Lundbeck to buy Longboard Pharma in $2.6 billion deal
Oct 14 (Reuters) - H Lundbeck A/S HLUNb.CO has agreed to buy US-based Longboard Pharmaceuticals LBPH.O in a $2.6 billion deal to boost its pipeline of treatments for neuro-rare conditions, the companies said on Monday. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
Recent news on H Lundbeck A/S
See all newsUBS upgrades Lundbeck to 'buy' on high epilepsy drug conviction
DB downgrades Lundbeck to 'sell' on Rexulti patent cliff risk
Europe Research Roundup: ASM International, Michelin, Nokian Renkaat
Europe Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Europe Research Roundup: BMW, Fugro, Mercedes-Benz